MSTN and arthritic joint disease: In addition, local or intraperitoneal administration of myostatin-specific antibody lessened bone erosion (−58, −31%, respectively), lowered inflammation (−42, −10%, respectively), and reduced osteoclast numbers (−36%) relative to vehicle-treated arthritic mice; suggesting a pharmacological myostatin-specific approach to mitigating inflammation joint destruction may be beneficial in arthritis (Dankbar et al., 2015).